REVIEW

ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Dannah R Miller1,2, Matthew A Ingersoll1,† and Ming-Fong Lin1,2,3,4,5

1Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
2Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA
3Section of Urology, Department of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
4Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA
5College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence should be addressed to M-F Lin: mlin@unmc.edu
†(M A Ingersoll is now at Department of Pharmacology, Creighton University, Omaha, Nebraska, USA)

Abstract

Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.

Key Words

- ErbB-2
- castration-resistant prostate cancer
- ErbB-2-targeting therapies
- ErbB-2 regulation

Introduction

Prostate cancer (PCa), one of the most common solid tumors, remains the second leading cause of cancer-related death in US men with an estimated 174,650 new cases in 2019 (Siegel et al. 2019). Early-stage localized PCa is well managed by surgery, radiation or a combination of both treatments; nevertheless, about 30% of the cases show regression and progression toward metastasis. Both localized and early stages of metastatic PCa cells rely on androgens for cell growth and progression; the removal of androgen via androgen deprivation therapy (ADT) results in cell cycle arrest or apoptosis of PCa cells, thereby these PCa cells are classified as androgen sensitive (AS). ADT, therefore, is the standard-of-care treatment for the management of metastatic PCa in its early stages. However, in most cases via a multitude of mechanisms, the metastasized cancer relapses, progresses and obtains the castration-resistant (CR) phenotype. Currently, patients with CR PCa only have limited treatment options that often fail shortly after implementation (Debes & Tindall 2004, Sartor & Gillessen 2014). Therefore, understanding the molecular networks underlying CR PCa progression will be beneficial for the design and development of therapeutic strategies for improving the management of CR PCa.

Protein tyrosine kinases (PTKs) are a large multigene family involved in key cellular processes regulating...
cellular development, differentiation and multicellular communication (Segaliny et al. 2015). Moreover, the perturbation of PTK signaling can result in the development of numerous disease conditions, including cancer (Regad 2015). One such mechanism that PCa cells utilize to obtain the CR phenotype is aberrant activation of androgen receptor (AR) and its downstream signaling pathways. Results of recent advances show that the activation of receptor tyrosine kinase (RTK) signaling, including ErbB-2, enhances CR PCa cell growth through subsequent effector pathways, such as mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) (McKay & Morrison 2007, Muniyan et al. 2015). Further, the autocrine growth factor loop of ErbB-1, ErbB-2 and ErbB-3 can activate AR and enhance CR PCa progression (Gao et al. 2016). This review focuses on discussing the oncogenic contribution of PTK ErbB-2 in mediating CR PCa progression and provides an update on our understanding of ErbB-2 regulation and signaling and its potential as a therapeutic target and/or biomarker in CR PCa.

Regulation of ErbB-2 protein-tyrosine kinase

Ligands associated with asymmetric dimerization and activation of ErbB-2

Current knowledge clearly shows that in a normal non-cancerous cell, ErbB-2 can only be activated through its heterodimerization with other ligand-bound ErbB family members. The binding of growth factors to ErbB-1/3/4 extracellular sub-domains I and III induces the conformational change, that is, closed conformation to open conformation, by exposing the dimerization interface of sub-domain II, which is otherwise buried within sub-domain IV, and promotes dimerization (Dawson et al. 2005, 2007) as shown in Fig. 1. In contrast, ErbB-2 maintains a naturally open conformation in which the dimerization arm of sub-domain II is exposed (Fig. 1). This is due to the substitution of a glycine residue with proline in sub-domain II as well as a histidine residue with phenylalanine in sub-domain IV, preventing sub-domain II and IV association in ErbB-2 (Cho & Leahy 2002).

As shown in Fig. 2, many known ligands include epidermal growth factor (EGF), epigen (EPG), transforming growth factor (TGFn), amphiregulin (AREG), Betacellulin (BTC), heparin-binding epidermal growth factor (HB-EGF) and epiregulin (EPR), which all can bind to ErbB-1/EGFR. Neuregulin (NRG)-1/2/3/4 are known ligands to both ErbB-3 and ErbB-4, while ErbB-4 can also bind to BTC, HB-EGF and EPR. Ligand binding to ErbB-1/3/4 induces a conformational change resulting in heterodimerization with ErbB-2 and protein kinase activation. The phosphorylation of multiple tyrosine residues creates docking sites for various adapter proteins such as Src homology 2 domain containing (Shc), growth factor receptor-bound protein 2 (Grb2), Src, protein tyrosine phosphatase-2c (PTP-2c), spleen tyrosine kinase (Syk), phospholipase Cγ (PLCγ), Src homology region 2 domain containing phosphatase-1 (SHP1), and so forth. The phosphorylation and subsequently docking with different adapter proteins initiates the diverse downstream signaling cascades, which can result in various cellular processes such as cell growth, differentiation, migration, adhesion and apoptosis (El Sheikh et al. 2004, Tome-Garcia et al. 2014).

Overproduction of ligand is one alternate method through which tumor cells achieve aberrant ErbB-2
activation, and the source of ligand can be either tumor cells or surrounding stroma. Elevated expression of ErbB ligands, including TGF-α, HB-EGF and AREG, are often associated with clinical prognosis in a number of cancers, including PCa (Salomon et al. 1995), which correlates with a poor clinical outcome (Normanno et al. 2003). Recent studies further demonstrated that PCa cells are capable of overexpressing ErbB-associated ligands EGF, BTC and NRG-1 to combat treatment with ErbB family inhibitors, including cetuximab, erlotinib or gefitinib (Carrion-Salip et al. 2012). Recently, phase I/II trials of rilotumumab, a monoclonal antibody inhibiting hepatocyte growth factor (HGF), have shown increased survival rates in patients with non-small-cell lung cancer (Tarhini et al. 2017). Therefore, investigation of competitive inhibitors of ErbB family ligands as well as inhibitors of ErbB ligand synthesis is suggested for potential treatment of PCa.

Interestingly, it has been shown that in advanced cancer cells, the ErbB-2 protein can homodimerize via its open subdomains II and IV, leading to self-activation upon its overexpression or lack of expression of its regulatory phosphatase (Meng & Lin 1998, Muniyan et al. 2015). Consistently, in the absence of ligand activation, overexpression of either EGFR or ErbB-2 in non-cancerous cells leads to the malignant transformation (Di Fiore et al. 1987). Several studies show that overexpression, mutation or loss of ErbB-2 expression results in dysregulation of dimerization and the downstream signaling of other ErbB proteins, indicating the importance of ErbB-2 in ErbB members signaling (Holbro et al. 2003, Dawson et al. 2005, Worthington et al. 2017). Nevertheless, the specific activation of respective signaling pathways requires further elucidation.

**Cellular prostatic acid phosphatase (cPAcP) dephosphorylates ErbB-2**

Upon heterodimerization, the cytoplasmic domain of ErbB-2 is hyper-phosphorylated at multiple tyrosine residues, leading to protein kinase activation. Therefore, the phosphatases that can reverse ErbB-2 tyrosine phosphorylation are capable of inhibiting its signaling cascade. Cellular prostatic acid phosphatase (cPAcP) is a dual specificity prostate-specific phosphatase that can dephosphorylate tyrosine, serine and threonine residues with a preference for phosphotyrosine (p-Tyr) residues (Lin & Clinton 1986). Importantly, results of several analyses on prostate adenocarcinoma archival specimens clearly show decreased cPAcP expression at both mRNA and protein levels, compared to adjacent non-cancerous cells (Veeramani et al. 2005). Among several PCa cell lines and within sublines of the same origin, in low PAcP-expressing PCa cells, ErbB-2 is hyper-activated by tyrosine phosphorylation, supporting a correlative of low cPAcP activity and high ErbB-2 activation by tyrosine phosphorylation (Meng & Lin 1998, Muniyan et al. 2015). Consistently, several lines of evidence further show that in PCa cells, ErbB-2 is a direct target of cPAcP including co-immunoprecipitation experiments, demonstrating the potential interaction between these two proteins.

The loss of cPAcP expression is an early event in PCa (Veeramani et al. 2005); therefore, it is proposed to be a prominent source of ErbB-2 hyperactivation commonly observed in PCa cells. Interestingly, when LNCaP-AS and MDA PCa2b-AS cells progress to the androgen-independent (AI) stage, that is, proliferation in androgen-reduced culture conditions and obtaining the CR phenotype seen in clinical PCa by expression of functional AR and PSA, ErbB-2 is hyper-phosphorylated and cPAcP protein levels decrease (Meng & Lin 1998, Muniyan et al. 2015). Additionally, cPAcP knockdown in LNCaP-AS cells results in increased ErbB-2 tyrosine phosphorylation and AI cell proliferation in cultures (Chuang et al. 2010, Muniyan et al. 2015). In those cells, there is no observed EGFR/ErbB-2 heterodimerization by co-immunoprecipitation (Veeramani et al. 2005). Conversely, PAcP cDNA transfection of cPAcP-deficient LNCaP-AS or cPAcP-null PC-3 PCa cells results in decreased ErbB-2 tyrosine phosphorylation as well as the reacquisition of the AS phenotype, indicating the role of cPAcP and ErbB-2 interaction is involved in regulating androgen sensitivity (Meng & Lin 1998, Chuang et al. 2010, Muniyan et al. 2015). Importantly, PAcP-knockdown of AS PCa cells via shRNA, but not the parental control cells, develop xenograft PCa tumors in female mice, androgen-deprived environments (Chuang et al. 2010, Muniyan et al. 2015), and the PAcP gene-knockout mice spontaneously develop prostate adenocarcinoma (Quintiero et al. 2013). Thus, in PAcP-deficient prostate epithelial cells, ErbB-2 is hyperactivated by tyrosine phosphorylation, contributing to enhanced PCa tumorigenicity. Increased cPAcP expression is thus a pending novel therapeutic strategy for the treatment of CR PCa.

Androgens, p66Shc and ROS enhance ErbB-2-specific activity

In AS PCa cells, androgen treatments induce tyrosine phosphorylation and activation of ErbB-2 which is associated with increased cell proliferation. Recent advances reveal that this is achieved in part via androgen-induced elevation of p66Shc protein, a 66 kDa proto-oncogene Src and collagen homologue (Shc), and one of three members of the Shc family including isoforms p52Shc and p46Shc (Alam et al. 2009, Rajendran et al. 2010). p66Shc differs from the other Shc isoforms in that it possesses oxidase activity, its protein half-life is increased by androgens, and importantly, its protein level is elevated in PCa archival specimens and correlates with the CR phenotype of PCa cells (Lee et al. 2004, Veeramani et al. 2008, 2012, Kumar et al. 2011). In PCa cells, p66Shc is localized in both cytosol and mitochondria. In androgen-treated PCa cells, p66Shc protein levels in mitochondria are elevated, where p66Shc binds to and oxidizes cytochrome C, uncoupling the electron transport chain to promote the production of cellular reactive oxygen species (ROS) (Veeramani et al. 2008, Kumar et al. 2011). In the cytosol of mouse embryonic fibroblasts (MEFs), p66Shc displaces Son of Sevenless 1 (SOS1), promotes Rac1 activity and stimulates NADPH oxidase (NOX) complex formation, leading to the generation of superoxide (Khanday et al. 2006). In AI PCa cells, elevated p66Shc protein results in enhanced Rac1 activation and cell proliferation as well as migration (Ingersoll et al. 2018).

ErbB-2 can be activated by cellular ROS. Veeramani et al. (2008, 2012) demonstrated that ErbB-2 is one of several downstream targets of p66Shc, and elevated expression of p66Shc, but not its oxidase-deficient mutant, in PCa cells results in increased ROS production, ErbB-2 tyrosine phosphorylation and cell growth rate. Similarly, treatment of AS LNCaP cells with hydrogen peroxide at physiological levels was shown to decrease cPAcP activity and increase p-Tyr1221/1222 levels of ErbB-2 and cell proliferation, which is counteracted by antioxidant N-acetyl cysteine (NAC). It was further determined that p66Shc/ROS-mediated inactivation of cPAcP phosphatase activity is at least one mechanism through which ErbB-2 activation is achieved (Veeramani et al. 2008, 2012). In summary, androgen upregulation of p66Shc protein levels (Kumar et al. 2011) results in increased cellular levels of ROS which oxidize and inactivate cPAcP, preventing cPAcP from dephosphorylating ErbB-2, which leads to ErbB-2 activation and PCa cells obtain the CR PCa phenotype.

miRNAs downregulate ErbB-2 protein levels

miRNAs are short, non-coding RNAs which post-transcriptionally regulate gene expression and are often aberrantly expressed in tumors. These molecules can regulate protein expression by binding to the 3′-untranslated regions of target miRNAs to suppress translation or induce degradation. While miR-125a and miR-125b can directly regulate ErbB-2 in breast cancer cells; they do not directly regulate ErbB-2 in PCa cells (Scott et al. 2007, Shi et al. 2008). miR-331-3p binds to the 3′-untranslated region of ErbB-2 in two target sites to regulate ErbB-2 protein expression in multiple PCa cell lines (Epis et al. 2009). Moreover, miR-331-3p is
expressed at a lower level in cancer cells compared to benign cell lines, and induction of miR-331-3p in cancer cells suppresses tumor phenotype through inhibition of PI3K/AKT signaling (Epis et al. 2009). Interestingly, human antigen R (HuR) is an RNA-binding protein with elevated levels in PCa, which competes with miR-331-3p for 3’-UTR-binding sites on ErbB-2 mRNA. It is thus proposed that loss of miR-331-3p and elevation of HuR can lead to increased ErbB-2 protein in the absence of gene amplification observed in a subset of advanced PCa tumors (Epis et al. 2011).

**Cholesterol and lipid-rafts enhance ErbB-2 signaling**

Hypercholesterolemia is associated with an increased risk of aggressive PCa via a multitude of mechanisms, including increased steroidogenesis, inflammation, proliferation and alterations in lipid rafts (Pelton et al. 2012). Lipid rafts are specialized domains located within the plasma membrane enriched with cholesterol, sphingolipids and various signaling proteins. G-protein-coupled receptors (GPCRs), glycosylphosphatidylinositol (GPI)-anchored proteins, Src family kinases and G-proteins such as Ras are associated with lipid rafts where they initiate signal transduction and amplification. ErbB family members are also shown to be associated with lipid rafts (Zhuang et al. 2002). In PCa cells, a small sub-population of ErbB-2 was found to be associated with lipid rafts, despite that the majority of ErbB-2 molecules are localized within the cytoplasm (Chinni et al. 2008). It should also be noted that a small subset of cPAcP was obtained by detergent extraction from the lipid fraction of non-cancerous prostate cells and that fraction is diminished in cancerous cells (Veeramani et al. 2005). Interestingly, the subpopulation of ErbB-2 located within lipid rafts of PCa cells has higher phosphorylation levels than ErbB-2 in non-raft membranes, and ErbB-2 signaling to downstream effectors is abrogated when cholesterol levels are reduced (Zhuang et al. 2002). For ErbB-2 targeting therapy, further investigation on lipid raft-associated ErbB-2 is warranted.

**CXCR4 transactivates ErbB-2 in lipid rafts**

C-X-C chemokine receptor type 4 (CXCR4) is a seven-transmembrane trimeric GPCR expressed in epithelial cancer cells. Currently, the only known ligand of CXCR4 is the C-X-C motif chemokine ligand 12 (CXCL12), an 11 kDa peptide expressed locally in the microenvironment of common metastatic sites, such as lung, bone and liver. Furthermore, binding of CXCL12 to CXCR4 has been shown to play a crucial role in site-specific metastasis to lymph nodes, lung and bone (Taichman et al. 2002, Chinni et al. 2006). GPCRs can transactivate ErbB family members by ectodomain shedding of membrane-bound ErbB family receptor ligands by proteases (Fischer et al. 2003) or by intracellular phosphorylation of ErbB family members via Src kinase (Fig. 2) (Luttrell & Luttrell 2004). CXCR4 and ErbB-2 are often co-localized at cell surface in lipid raft domains. CXCR4 overexpression can enhance ErbB-2 phosphorylation and is proposed to promote metastasis and invasion of PCa cells to the bone (Chinni et al. 2006, Conley-LaComb et al. 2016). Interestingly, in breast cancer, ErbB-2 has been shown to transactivate CXCR4 as well, leading to activation of Rac1 and subsequent cell migration (Li et al. 2004). Further elucidation on the interaction of CXCR4 and ErbB-2 may lead to alternate targeting therapies.

**Src activates ErbB-2, FAK and PYK2 to enhance PCa tumorigenicity**

Src kinase is a non-receptor tyrosine kinase localized in both lipid rafts and nonlipid rafts of PCa cells. Within the lipid raft, Src kinase activation is required for serving as the intermediate for CXCL12/CXCR4-induced ErbB-2 phosphorylation (Fig. 2). Src kinase associates with the carboxyl-terminal region of ErbB-2 through its SH2 domain and also promotes the heterodimerization of ErbB-2/ErbB-3 complex formation (Ishizawar et al. 2007). In addition, Src can be an upstream kinase of ErbB-2 in the nonlipid raft domain in PCa cells. The interaction of Src with ErbB-2 is shown to be required for ErbB-2-mediated invasive and migratory properties of epithelial cells (Conley-LaComb et al. 2016). Src can also be a downstream target of ErbB-2 and is upregulated in PAcP-knockdown cells in which ErbB-2 is activated by tyrosine hyperphosphorylation (Veeramani et al. 2005). ErbB-2 can promote Src stabilization and protein synthesis (Tan et al. 2005) as well as increase Src-specific activity (Muthuswamy et al. 1994) to promote cell adhesion, migration and invasion via focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PYK2) (Yuan et al. 2007). FAK and PYK2 are structurally related non-receptor protein tyrosine kinases that can compensate for one another if either protein is lost. Both proteins interact with integrins and GPCRs to promote cell motility or adhesion via c-Src kinase, extracellular-signal-regulating kinase (ERK)/MAPK, p38/MAPK and paxillin. Thus, both FAK and PYK2 contribute to cancer cell adhesion, proliferation and invasion. Nevertheless, in PCa cells, it was clearly
shown that in AR-positive PCa cells, ErbB-2 expression and activation correlates with PYK2 activation, leading to cell adhesion (Yuan et al. 2007), whereas FAK activity correlates with ErbB-2 expression in AR-negative PCa cells (Yuan et al. 2007, Johnson et al. 2008). The differential roles of PYK2 vs FAK in mediating ErbB-2 signaling in advanced PCa progression requires further investigation.

**Downstream targets of ErbB-2 in PCa progression**

**ErbB-2 promotes PCa cell proliferation and migration via PI3K/AKT**

Deregulation of protein kinase B (PKB), commonly referred to as AKT, is pervasive in PCa progression due to its regulation of mechanisms critical to metastasis. AKT plays a role in diverse cellular signaling, including cell survival, proliferation, migration, invasion and other biological events associated with carcinogenesis and cancer progression (Roy et al. 2002, Saxena et al. 2007). Further, AKT activation via T308/S473 phosphorylation is primarily regulated by the PI3K/phosphatase and tensin homolog (PTEN) axis as shown in Fig. 3 (Bellacosa et al. 1998). Once activated by RTKs such as ErbB-2, PI3K converts phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3), which activates a number of downstream signaling components, the most notable of which is AKT (Hodgkin et al. 2000). Conversely, PTEN catalyzes the opposite reaction, hydrolyzing PIP3 to PIP2 and preventing the activation of AKT (Maehama & Dixon 1998). In PCa, loss of PTEN function occurs in advanced PCa progression (Wang et al. 2003, Ozen et al. 2008). Interestingly, cPAcP (ErbB-2 activates the MAPK/ERK pathway to promote PCa tumorigenicity section) can also hydrolyze PIP3 (Muniyan et al. 2014). In PTEN-active, PAcP-deficient DU145 PCa cells, AKT is hyperactivated. Furthermore, in PTEN-inactive, cPAcP-expressing LNCaP-AS cells, AKT with low or no phosphorylation or activation; while in PAcP-deficient LNCaP-AS cells, AKT is hyperactivated by T308/S473 phosphorylation, similar to PTEN- and PAcP-null PC-3 cells. It is thus proposed that cPAcP is a PTEN-functional homologue in prostate epithelia (Muniyan et al. 2014). Because knockout of PAcP expression in mice results in the development of prostate adenocarcinoma (Quintero et al. 2013) and cPAcP expression is significantly reduced in primary PCa (Veeramani et al. 2005, Muniyan et al. 2014), it is hypothesized that decreased cPAcP expression in part by epigenetic modifications is involved in PCa development and the early stages of PCa progression, while PTEN plays a role in advanced PCa progression (Muniyan et al. 2014, Chou et al. 2015).

Upon activation, AKT regulates a number of cellular processes critical to PCa survival and progression. For example, AKT promotes cell survival by inactivating pro-apoptotic proteins, such as p53, BAX, BAD, BCL-2, BCL-XL and Survivin (Peliciano et al. 2006, Dhanasekaran et al. 2008). AKT also promotes cell proliferation by enabling the cell to overcome cell cycle arrest at the G1 and G2 phases through activation of Cyclin D1, Cyclin-dependent kinase A (CDKA) and CDK6 as well as activating other pro-growth signaling molecules such as mammalian target of rapamycin (mTOR) (Liang & Slingerland 2003). Additionally, AKT promotes angiogenesis through vascular endothelial growth factor (VEGF) activation as well as cell migration and invasion through regulation of cadherin proteins, MYC,
matrix metalloproteinases, Snail and Forkhead box protein M1 (FOXM1) (Gera et al. 2004, Julien et al. 2007, Jin et al. 2015, Ingersoll et al. 2018). AKT also promotes cholesterol synthesis, which is utilized by over 50% of advanced prostate tumors for de novo androgen synthesis (Zhuang et al. 2005, Dillard et al. 2008). Thus, AKT is capable of promoting the aggressive metastatic phenotype of PCa.

In PCa, AKT and AR share an interconverting complex signaling network in which each protein is capable of regulating the other. Through p66Shc elevation, AR indirectly increases cellular ROS levels, which leads to the inactivation of phosphatases, such as cPAcP (Veeramani et al. 2012). By preventing cPAcP-mediated dephosphorylation and inhibition of ErbB-2, AR also promotes the activation of a number of ErbB-2-regulated pathways such as the PI3K/AKT pathway (Veeramani et al. 2012). Conversely, AKT can modulate the transcriptional activity of AR through direct phosphorylation. For example, phosphorylation of AR at S210 and S790 by AKT suppresses AR-mediated apoptosis and contributes to PCa survival (Lin et al. 2003). Further, AKT can bind and phosphorylate AR at S213, which increases AR ligand-binding and promotes AR activation and translocation to the nucleus (Wen et al. 2000). Moreover, in the event of AR inhibition or androgen deprivation, the PI3K/AKT pathway is reported to be activated in PCa cells as a mechanism of androgen independence. Clearly, AKT is a useful therapeutic target for CR PCa treatment (Wen et al. 2000).

### ErbB-2 activates the MAPK/ERK pathway to promote PCa tumorigenicity

In addition to AKT, activated ErbB-2 also activates the MAPK pathway, which includes ERK1/2 (Zhang et al. 2001, Agus et al. 2002, Chuang et al. 2010). These proteins are frequently reported to be activated in aggressive PCa and are key regulatory kinases for processes vital to PCa development and progression (Zhang et al. 2001, Oshikawa et al. 2012, Veeramani et al. 2012). Figure 3 demonstrates that at the cell membrane, activated RTKs initially recruit Shc and/or Grb2 with SOS1 to facilitate GDP-GTP nucleotide exchange on Ras (McKay & Morrison 2007). Ras then activates Raf kinase that subsequently activates MAPK/ERK kinase (MEK), which finally activates ERK1/2 via T202 and Y204 phosphorylation (Schlessinger 2000, McKay & Morrison 2007). ERK is a serine-threonine kinase and its isoforms include ERK1 and ERK2 according to their coding sequences. ERK1/2 is highly activated in advanced AI PCa (Gioeli et al. 1999). Activated ERK regulates several processes critical to PCa progression including survival, proliferation and migration via activation of transcription factors such as Elk1 (Kue et al. 2002, Gao et al. 2006, Kinkade et al. 2008). Similar to AKT, ERK and AR signaling pathways undergo dynamic crosstalk and feedback loops (Ballaré et al. 2003, Recchia et al. 2009). Through ErbB-2 regulation, AR is able to promote downstream activation of ERK (Recchia et al. 2009, Chia et al. 2011). In turn, ERK can regulate AR through induction of cAMP-responsive element-binding protein 1 (CREB1) transcription factor that binds to the AR promoter and enhances its transcription (Chia et al. 2011). ERK is also capable of direct phosphorylation of AR and its coregulators, resulting in AR activation and promoting its translocation to the nucleus (Gioeli et al. 2006, Recchia et al. 2009, Chia et al. 2011). Thus, due to its promotion of the metastatic phenotype as well as induction of AR signaling, ERK is a potential therapeutic target for CR PCa treatment (Zelivianski et al. 2003).

### STATs induce transcription upon activation by ErbB-2

The signal transducer and activator of transcription (STAT) proteins are indispensable in the development and progression of a wide variety of cancers. In PCa cells, loss of cPAcP expression and thus constitutive activation of ErbB-2 results in the activation of STAT-3 and STAT-5 via protein phosphorylation (Chuang et al. 2010). STAT-3 can be involved in promoting cell proliferation, anti-apoptosis, angiogenesis, inflammation and also epithelial-to-mesenchymal transition (EMT) in PCa progression (Bishop et al. 2014). In PCa, STAT-3 can promote the transcription of AR downstream targeted gene, prostate-specific antigen (PSA), via STAT-3 interaction with the N-terminal domain of AR. Interleukin-6 (IL-6)-mediated activation of STAT-3 and AR is also associated with trans-differentiation of LNCaP cells to obtain the neuroendocrine (NE) phenotype (Spiotto & Chung 2000, Yuan et al. 2007). Further, the IL-6 receptor can also cooperate with ErbB-2 to activate the MAPK pathway upon short-term IL-6 treatment to promote AR activity (Lin et al. 2001). IL-6 was proposed to serve as a useful biomarker for the detection of PCa as well as the extent of the disease (Nakashima et al. 2000). Unfortunately, as a cancer diagnostic marker, IL-6 fails because it can be secreted and elevated under many pathological conditions including cancers (Azevedo et al. 2011), making it difficult to deduce what type of cancer or disease a patient has developed.
ErbB-2 as a prognostic marker

ErbB-2 hyperactivation/tyrosine phosphorylation in human PCa progression

Several lines of evidence have clearly shown the increased ErbB-2 activation, but not protein levels, upon progression from the AS to the AI stage in LNCaP and MDAPca2b cells (Meng & Lin 1998, Chuang et al. 2010, Muniyan et al. 2015). Activation of ErbB-2 via tyrosine phosphorylation is required for cell growth in both AS and AI PCa cells. In AS PCa cells, DHT-stimulation of cell proliferation is mediated by ErbB-2 tyrosine phosphorylation. In AR-positive PCa cells, ErbB-2 activation, in part due to the loss of cPAcP expression, can enhance AR activity, cell survival and AI progression, thus those cells obtain the CR phenotype (Tome-Garcia et al. 2014, Muniyan et al. 2015). While ErbB-2 phosphorylation status has not yet been analyzed in clinical PCa samples, ErbB-2 hyperphosphorylation has the potential to be a promising biomarker for the disease state of PCa.

ErbB-2 activation involving the metastatic tumor phenotype and castration resistance of PCa

Results of several studies have shown that ErbB-2 protein level is elevated in a small subset of CR PCa tissue samples (Gregory et al. 2005, Montironi et al. 2006, Minner et al. 2010) and correlates with poor disease prognosis (Carles et al. 2004, Edwards et al. 2006). A consensus on the role of ErbB-2 activation in AI PCa has emerged. Activation of ErbB kinases, particularly ErbB-2, can result in the transcription and activation of AR via MAPK (Tome-Garcia et al. 2014). Constitutively active ErbB-2 also promotes AKT activation, which can thereby activate AR to enhance the transcription of androgen-regulated genes to promote AI growth of PCa cells (Craft et al. 1999, Wen et al. 2000, Lee et al. 2003, Mellinghoff et al. 2004).

Importantly, ErbB-2 activation has been demonstrated in abiraterone-resistant CR PCa as well, resulting in activation of AR via AKT (Gao et al. 2016). Additionally, ErbB-2, but not other members of the ErbB family, in AI proliferation is demonstrated in various PCa cells (Hsu et al. 2011, Muniyan et al. 2015). Interestingly, ErbB-2 activation was shown to be associated with promoting a NE-like phenotype in PCa via an AKT-independent mechanism (Cortez et al. 2012). Recent advances link EGFR/ErbB-2 signaling to promotion of PCa stem cell renewal and stem cell-mediated PCa metastasis to the bone (Rybak et al. 2013, Day et al. 2017).

Clearly, ErbB-2 hyper-activation, but not ErbB-2 protein elevation, plays a critical role in advanced PCa progression.

ErbB-2 as a therapeutic target for PCa/CR PCa

Inhibitors of ErbB protein kinase domain have limited efficacy against PCa

Due to the lack of a known ligand for ErbB-2 and the general requirement of heterodimerization of ErbB-2 with other ErbB family members for its activation, targeting EGFR is proposed to be a potential approach for treating cancers that require ErbB-2 signaling as shown in Table 1. EGFR inhibitors erlotinib and gefitinib target the kinase domain of EGFR and thus prevent tyrosine phosphorylation and block downstream signaling. Unfortunately, PCa cells are capable of overexpressing ErbB-associated ligands to combat treatment with ErbB family inhibitors, including erlotinib and gefitinib, leading to limited efficacy of these agents. Furthermore, erlotinib-resistant PCa cells were shown to have increased ErbB-2 and ErbB-3 mRNA and protein levels to promote the activation of the PI3K/AKT pathway. Erlotinib resistance in PCa cells could be overcome upon monoclonal antibody blockage of ErbB-3 (Carrion-Salip et al. 2012). While other EGFR inhibitors, such as ZD1839 (Iressa), have shown some promising results in clinical trials for treatment of a variety of cancers further investigation is required in PCa (de Bono & Rowinsky 2002).

Because small molecule inhibitors cannot specifically target ErbB-2 alone, dual EGFR/ErbB-2 inhibitors are currently being developed. CI-1033 is a pan-ErbB irreversible inhibitor which was well tolerated by patients in phase I clinical trials; however, this molecule was not as effective as desired and is no longer involved in clinical trials (Campos et al. 2005). Lapatinib is a tyrosine kinase inhibitor that obstructs both EGFR and ErbB-2 signaling and has had great efficacy with reducing tumor growth in breast cancer patients (Blackwell et al. 2010); however, further studies are required in treating CR PCa patients. At this time lapatinib is not being pursued in a clinical setting, however previous studies suggest analyzing patients for predictive biomarkers and combination with other anti-cancer agents (Whang et al. 2013). Recently, a potent orally available dual EGFR/ErbB-2 inhibitor HKI-272 (Neratinib) was developed using a homology model for the catalytic domain of ErbB-2 and has since entered phase I clinical trials (Wissner et al. 2003). This molecule effectively inhibits both ErbB-2 and EGFR.
irreversibly in vitro, resulting in abrogated signaling through MAPK and AKT. HKI-272 also has great efficacy against xenograft breast tumors, and oral administration of this compound was well tolerated in mice (Rabindran et al. 2004). Results of clinical trials on the efficacy of HKI-272 in PCa have not been reported at this time. BIBW-2992 (Afatinib) is another potent oral dual EGFR/ErbB-2 inhibitor underwent clinical trials in PCa in combination with an anti-angiogenic agent as well as in combination with docetaxel (Reid et al. 2007). Unfortunately, the phase II study in CR PCa patients revealed that BIBW-2992 only exhibits limited anti-tumor activity (Molife et al. 2014). As such, ErbB-2 TKIs alone may not be a suitable method for treating CR PCa (Table 1).

### ErbB-2 targeting vaccine can treat ErbB-2-overexpressing PCa

Peptide-based vaccines targeting the extracellular domain of ErbB-2 were one of the initial therapies for ErbB-2-expressing cancers (Disis et al. 1999). Using a peptide vaccine approach with granulocyte macrophage-colony-stimulating factor (GMCS) as an adjuvant, ErbB-2 proteinspecific T-cell responses are generated in patients with breast and ovarian tumors that overexpress ErbB-2 (Disis et al. 1999). A study by Bhattacharya et al. showed a vector encoding the fusion protein of a truncated sequence of the ErbB-2 extracellular domain and the N-terminal sequence of EGFR effectively induces enhanced antitumor immunity against PCa cells expressing the cognate tumor-associated antigen (Bhattacharya et al. 2002). While many studies have since been focused on ErbB-2 vaccine developments; the availability of a suitable preclinical model is a major challenge. Rat ErbB-2 (neu) transgenic models are inadequate due to the 10% difference in sequences between neu and ErbB-2, while subcutaneous transplant xenograft models do not readily metastasize (Yamamoto et al. 1986, Piechocki et al. 2003). Moreover, because ErbB-2 is infrequently overexpressed in PCa, a vaccine would likely only be effective against a small subpopulation of PCa tumors that have elevated ErbB-2 protein levels. At this time, ErbB-2 vaccines have yet to enter clinical trials in PCa patients.

### cPACP intratumoral expression reduces ErbB-2 activity and tumorigenicity in PCa tumors

As described above in ‘Cellular Prostatic Acid Phosphatase (cPACP) Deyphosphorylates ErbB-2’ section, several lines of evidence have clearly demonstrated that cPACP is a negative regulator of ErbB-2 phosphorylation and activation. Accordingly, suppression of ErbB-2 activity through intratumoral expression of cPACP has the potential as a PCA therapy (Igawa et al. 2003, Table 1). Studies in PCa xenograft tumor models show that abrogation of ErbB-2 activity in established subcutaneous AI LNCaP C-81 tumors with an intratumoral injection of

---

**Table 1** ErbB-2 therapies utilized for PCa.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Method of action</th>
<th>Efficacy against PCa (in vivo and clinical trials)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erlotinib</td>
<td>EGFR inhibitor</td>
<td>Limited antitumor activity in vivo</td>
<td>Carrière-Salip et al. (2012)</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>EGFR inhibitor</td>
<td>Limited antitumor activity in vivo</td>
<td>Carrière-Salip et al. (2012)</td>
</tr>
<tr>
<td>ZD1839 (Iressa)</td>
<td>EGFR inhibitor</td>
<td>Effectively reduced PCa growth in patients</td>
<td>de Bono &amp; Rowinsky (2002)</td>
</tr>
<tr>
<td>Cl-1033</td>
<td>Pan-ErbB inhibitor</td>
<td>Limited antitumor activity in patients</td>
<td>Campos et al. (2005)</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Dual EGFR/ErbB2 inhibitor</td>
<td>Undergoing phase I trials; effectively reduced xenograft tumors</td>
<td>Blackwell et al. (2010)</td>
</tr>
<tr>
<td>HKI-272</td>
<td>Dual EGFR/ErbB2 inhibitor</td>
<td>Limited antitumor activity in patients</td>
<td>Wisnner et al. (2003),</td>
</tr>
<tr>
<td>BIBW-2992</td>
<td>Dual EGFR/ErbB2 inhibitor</td>
<td>N/A</td>
<td>Rabindran et al. (2004)</td>
</tr>
<tr>
<td>ErbB-2 vaccine</td>
<td>ErbB-2-targeted T cell response</td>
<td>Effectively reduced PCa xenograft tumors</td>
<td>Reid et al. (2007),</td>
</tr>
<tr>
<td>cPACP cDNA intratumoral injection</td>
<td>Overexpression of negative regulator</td>
<td>Effective in PCa if ErbB-2 overexpressed in tumors</td>
<td>Molife et al. (2014),</td>
</tr>
<tr>
<td>Trastuzumab (Herceptin)</td>
<td>Anti-ErbB-2 antibody; reduces ErbB-2 protein</td>
<td>Delays CR PCa disease progression; clinical trial terminated</td>
<td>Bhattacharya et al. (2002),</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>Anti-ErbB-2 antibody; blocks dimerization</td>
<td></td>
<td>Piekochi et al. (2003),</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Igawa et al. (2003)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ziada et al. (2004)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Agus et al. (2007)</td>
</tr>
</tbody>
</table>

Several attempts have been made to target ErbB-2 in PCa through a variety of methods. Results of in vivo mouse studies as well as patient clinical trials have shown some therapies can effectively reduce PCa growth while others have limited anti-tumor activity. Furthermore, many of these studies have demonstrated that the utilization of ErbB-2-targeting therapies require a specific patient sub-population in which the tumors rely on ErbB-2 signaling for proliferation and/or survival.
expression vector containing the wild-type cPAcP cDNA results in concomitant suppression of tumor growth. Nevertheless, a PTPase enzymatically-dead mutant of cPAcP, which lacks its ability of dephosphorylating ErbB-2, has reduced tumor-suppressive activity (Igawa et al. 2003). Together, the data indicates that inhibition of ErbB-2 activity is critical for the suppression of prostate adenocarcinoma, and restoration of PAcP expression is an alternate approach for PCa/CR PCa therapy.

**Immunotherapy impedes ErbB-2 signaling in ErbB-2-overexpressing PCa**

Various studies have investigated the potential of anti-ErbB-2 monoclonal antibodies to reduce ErbB-2 expression in ErbB-2-transformed NIH3T3 cells and reverse their transformed phenotype including tumorigenicity and metastasis in xenograft mouse models (Drebin et al. 1986, 1988, Yu & Hung 2000). Importantly, anti-ErbB-2 murine monoclonal antibody (muMAB 4D5) has been used to develop the humanized antibody trastuzumab (Herceptin) that binds to the extracellular domain of ErbB-2 to reduce cell-surface ErbB-2 proteins (Shepard et al. 1991). In ErbB-2 amplified breast cancer, trastuzumab has demonstrated to effectively inhibit tumor growth and sensitize to several chemotherapeutic agents, such as docetaxel, in preclinical studies as well as in phase II and phase III clinical trials and is now FDA approved for treating ErbB-2-overexpressing breast cancers (Pegram et al. 1998, Pietras et al. 1998, Agus et al. 1999, Table 1).

Studies of trastuzumab in PCa xenograft models have demonstrated antitumor activity, while clinical trials in men with advanced PCa showed little efficacy because PCa cells rarely overexpress ErbB-2 and trastuzumab is most effective when cells express high levels of ErbB-2 (Baselga et al. 1999, Ziada et al. 2004). Another ErbB-2 targeting monoclonal antibody, pertuzumab, targets a different extracellular domain than trastuzumab and strictly blocks the association of ErbB-2 with other ErbB members thus preventing signaling in both high and low ErbB-2-expressing tumor cells (Agus et al. 2002). Importantly, pertuzumab has shown to delay disease progression in CR PCa patients (Agus et al. 2007). Currently, pertuzumab is approved by FDA only for breast cancer treatment; nevertheless, one clinical trial analyzing the efficacy of pertuzumab in PCa patients was terminated due to insufficient therapeutic response (de Bono et al. 2007). Although this study ultimately failed, screening of PCa tumor samples for the reliance of the cancer on ErbB-2 signaling and directing the study toward the CR PCa patient population may increase the effectiveness of pertuzumab treatment for a subpopulation of PCa patients. Currently, clinical trials on ErbB-2-targeted immunotherapies continue to recruit PCa and CR PCa patients, thus suggesting the potential of this avenue of treatment can be beneficial for a particular patient population and/or in combination with other therapeutic agents.

**Promising ErbB-2 combination treatments for CR PCa**

Although many clinical trials analyzing the effectiveness of ErbB-2 as a single therapeutic target have ended with unfavorable results, combination therapies including these molecules have shown promise and should be subjected to further analysis in clinical trials. Upon termination of the phase II clinical trial of pertuzumab in CR PCa, de Bono et al. (2007) suggested that the lack of efficacy of pertuzumab could likely be due to intraprostatic androgen signaling. As such, several lines of study have analyzed the effects of inhibition of ErbB-2 in the presence of anti-androgens. Interestingly, the risk of recurrence of PCa xenograft tumors was significantly reduced when castration or anti-androgens were combined with trastuzumab or mTOR inhibitor everolimus (Guyader et al. 2012). The combination of lapatinib and enzalutamide also has shown synergistic anti-tumor effects in CR PCa (Shiota et al. 2015), and castration in combination with herbal extract of Wedelia chinensis greatly reduced CR PCa growth via disruption of ErbB-2, AKT and AR signaling (Tsai et al. 2017, Table 1). Together, these data suggest that clinical trials would be more successful with combination of ErbB-2 inhibitors and anti-androgens and thus warrants further investigation.

**Conclusion and future perspectives**

In summary, ErbB receptors are vital to many signaling events and are indispensable for cancer cell survival in a variety of cancer subsets, including those in PCa. ErbB-2 is a unique member within this family as it currently does not have a known ligand; ErbB-2 activation in general requires heterodimerization with another activated ErbB family member. Therefore, ErbB-2 can be regulated by a variety of ligands binding to other ErbB family members as well as a variety of intracellular proteins. Conversely, protein phosphatase cPAcP has been demonstrated to negatively regulate ErbB-2 enzymatic activity via protein dephosphorylation, and miR-331-3p reduces ErbB-2 mRNA levels. ErbB-2 activity can also be positively
regulated by androgens, oxidase p66Shc, CXCR4 and Src. ErbB-2 downstream targets include AKT, ERK and STAT proteins, and upon activation of these proteins, there is promotion of tumor progression, including cell growth, survival and migration, as demonstrated in Fig. 3. As such, results of several studies have indicated that ErbB-2 protein or its hyper-phosphorylation levels could be analyzed for potential utilization as a biomarker for the progression of PCa and other steroid hormone-regulated cancers. In parallel, several approaches to target ErbB-2 activity have been investigated, including dual EGFR/ ErbB-2 inhibitors, ErbB-2 vaccine and immunotherapy as shown in Table 1. Unfortunately, most of these ErbB-2-targeted single therapies have limited antitumor activity in clinical trials for PCa. Thus, development of anticancer agents that target ErbB-2 regulatory molecules or downstream proteins may be a more promising method to reduce deaths due to CR PCa, in addition to combination therapies with anti-androgens. For example, dual targeting of ErbB-2 and PI3K has been shown to be an effective means of growth suppression in breast cancer (Junttila et al. 2009, Rexer et al. 2014, Choi et al. 2018) that could be translated to CR PCa.

Moving forward, ErbB-2 remains an important molecule in the context of PCa, especially in advanced disease progression. Significantly, the analysis on ErbB-2 phosphorylation status in patient PCa samples should be performed to determine if altered phosphorylation of ErbB-2 is seen upon disease progression to the CR stage, as observed in the PCa cell progressive model (Meng & Lin 1998, Chuang et al. 2010, Wu et al. 2010, Muniyam et al. 2015). As such, restoration of cPACp expression may serve as an alternative for CR PCa therapy. Furthermore, the role of ErbB-2 in PCa stem cell and NE-like cell differentiation is still poorly understood and warrants further investigation. Understanding the unique signaling pathway of ErbB-2 in CR PCa cells will help identify novel targets for CR PCa therapy, such as the novel approach to restore cPACp expression or knockdown of p66Shc protein.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This study was supported in part by the National Institutes of Health (CA88184), the US Department of Defense PCRP Grant (PC121645, and PC141559), the University of Nebraska Food for Health Grant, the University of Nebraska Medical Center Bridge Fund, the Buffet Cancer Center Pilot Project Grant, the University of Nebraska Medical Center Cancer Biology Training Grant (T32CA009476), the University of Nebraska Medical Center Graduate Fellowship and the Purdue Pharma Scholars Award.

References


Dillard PR, Lin MF & Khan SA 2008 Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Molecular and Cellular Endocrinology 298 115–120. (https://doi.org/10.1016/j.mce.2008.08.013)


Drebin JA, Link VC, Weinberg RA & Greene MI 1986 Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. PNAS 83 9129–9133. (https://doi.org/10.1073/pnas.83.23.9129)


ErbB-2 in advanced prostate cancer


Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FE & Lin MF 2003 ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 22 781–796. (https://doi.org/10.1038/sj.onc.1206066)


McKay MM & Morrison DK 2007 Integrating signals from RTKs to ERK/ MAPK. Oncogene 26 3113–3121. (https://doi.org/10.1038/sj.onc.1201394)


Meng TC & Lin MF 1998 Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in...


Piechocki MP, Ho YS, Pilon S & Wei WZ 2003 Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. *Journal of Immunology* **171**:5787–5794. (https://doi.org/10.4049/jimmunol.171.11.5787)


[Endocrine-Related Cancer](https://erc.bioscientifica.com)

© 2019 Society for Endocrinology

Published by Bioscientifica Ltd.

Printed in Great Britain
and therapeutic interests for bone cancers. Journal of Bone Oncology 4 1–12. (https://doi.org/10.1016/j.jbo.2015.01.001)


Spitto MT & Chung TD 2000 STAT3 mediates IL-6-induced signaling by p66Shc is involved in regulating androgenic growth independent proliferation of prostate cancer. Prostate 42 186–195. (https://doi.org/10.1002/(SICI)1097-0455(20000201)42:3<186::AID-PROS4>3.0.CO;2-E)


Received in final form 11 February 2019
Accepted 13 February 2019
Accepted Preprint published online 13 February 2019